|
|
Article: OrthoLogic Announces Label Changes for Hyalgan; Revised Package Insert Statements Extend Pain Relief Duration; Affirm Safety of Retreatment.
- Article from:
- Business Wire
- Article date:
- January 24, 2000
CopyrightCOPYRIGHT 2000 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors &Health/Medical Writers
TEMPE, Ariz.--(BW HealthWire)--Jan. 24, 2000
OrthoLogic Corp. (Nasdaq:OLGC) today announced that the U.S. Food and Drug Administration has approved new labeling for Hyalgan that includes extended pain relief offered by a single course of therapy and no longer has safety restrictions on retreatment.
Hyalgan (sodium hyaluronate) is a product administered by injection directly into the knee joint for relief of pain in mild to moderate osteoarthritis of the knee. Hyalgan has been in use for more than 12 years, with approximately 5 million injections given to date, making it the world's most widely prescribed ...